fda approves first oral glp-1 obesity drug august 21 2025 The approved a new pill from Eli Lilly on Wednesday. The drug, called Foundayo, is the second GLP-1 weight-loss pill. CBS News' Dr. LaPook has more on the new medication FDA approves weight loss pill
Description
Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons

This was thought related to the rapid glucose lowering in patients with pre-existing diabetic retinopathy (a known phenomenon where quick improvement of blood sugar can transiently worsen retinopathy)

Balancing price, safety and efficacy remains key in choosing a GLP-1 medication
These findings suggest potential neuroprotective benefits of semaglutide, especially regarding cognitive health, and call for further research to validate its use in treating cognitive deficits and substance misuse in patients with T2DM (87)

Gastrointestinal effects Nausea dominates the side effect landscape

Further purification of a polypeptide demonstrating enterogastrone activity
